Last reviewed · How we verify
Parenteral /oral methadone ratio 1:1.2
Methadone is a synthetic opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and suppress withdrawal symptoms.
Methadone is a synthetic opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and suppress withdrawal symptoms. Used for Opioid use disorder maintenance treatment, Chronic pain management, Opioid withdrawal syndrome.
At a glance
| Generic name | Parenteral /oral methadone ratio 1:1.2 |
|---|---|
| Also known as | Eptadone (1mg/ml) oral solution |
| Sponsor | L'Hospitalet de Llobregat |
| Drug class | Opioid agonist |
| Target | Mu opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain management; Substance use disorder |
| Phase | Phase 3 |
Mechanism of action
Methadone acts as a full mu opioid receptor agonist with a long half-life, making it suitable for maintenance therapy in opioid use disorder and chronic pain management. The 1:1.2 parenteral-to-oral ratio indicates the relative potency difference between intravenous/intramuscular and oral administration routes, reflecting differences in bioavailability and first-pass metabolism.
Approved indications
- Opioid use disorder maintenance treatment
- Chronic pain management
- Opioid withdrawal syndrome
Common side effects
- Constipation
- Sedation
- Sweating
- Respiratory depression
- QT prolongation
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: